Todd Roberts CEO & Co-founder

ATDev (Orange, CA, USA) is a robotic medical device company spun out of UC Berkeley. We have developed a low-cost robotic device, Reflex, for rehabilitation of orthopedic injuries and surgeries.

Therapeutic: Robotics; Orthopedic Rehabilitation

John Slump CEO & Co-founder

Atraverse Medical is a San Diego-based medical device company formed in July 2022 by the same founding team as FARAPULSE. The company is pioneering next-generation transseptal access with their innovative HOTWIRE™ system. FDA-cleared in May 2024, the HOTWIRE features universal sheath compatibility, optimized RF biophysics, and enables zero-exchange workflows.

Therapeutic: Cardiovascular

Anita Brinks COO

ATRO Medical (Nijmegen, Gelderland, The Netherlands) develops the sports medicine innovation of the decade: the first artificial meniscus. The Artimis Meniscus Prosthesis is designed to serve as a new shock absorber in the knee joint, providing relief to all those patients who's meniscus have been removed, but still suffer from chronic pains afterwards. Artimis has received FDA Breakthrough status, is in an ongoing multi-center clinical study and has positive clinical data.

Therapeutic: Orthopedics-Spine

Ilan Uchitel Co-Founder & CEO

CAPS Medical (Israel) has developed a proprietary PlasmaSure technology that uses Non Thermal Plasma (NTAP) to selectively target tumors through minimally invasive procedures. The PlasmaSure system uses existing minimally invasive tools and robotic systems, targeting a $100B TAM. CAPS effectively eliminates cancerous cells while preserving healthy tissue, allowing treatments to move from the operating room into a doctor's clinic. The technology is clinically tested and applicable to wide range of tumors.

Therapeutic: Oncology

Shawn Zhuang CEO

Cardiostory (San Francisco, CA, USA) is remote monitoring solution for heart failure patients. Those patients are repeatedly sent to hospital, because the pressure inside their heart is getting out of the range. Cardiostory offers a non-invasive device to measure this pressure which can only be measured invasively before. We used unique fiber optic sensors to capture micro-vibrations from the chest. We mapped these vibrations to how the heart is working inside. Based on that, we built a software algorithm to calculate the filling pressure inside the heart.

Therapeutic: Cardiology

Evan Luxon CEO

Centese (Omaha, NE, USA) is revolutionizing post-surgical care with Thoraguard®, the first autonomous system for managing thoracic drainage. Thoraguard provides automated fluid management and precise, real-time measurements, leading to shorter hospital stays with fewer complications. Proven in over 8,000 patients, Thoraguard sets a new standard for recovery following lung and heart surgery while streamlining clinical workflows and cutting costs for hospitals.

Therapeutic: Surgery; Digital Surgery

Julia DeVincenzo Director of Customer Advocacy and Clinical Education

Amma by Cooler Heads (San Diego, CA USA) is the only FDA cleared platform that allows chemotherapy patients to keep their hair that is profitable for infusion centers.

Therapeutic: Oncology

Michael Maglin CEO

NeuroPass™ from CraniUS Therapeutics (Baltimore, MD, USA) is a groundbreaking, fully implantable drug delivery system that bypasses the blood-brain barrier, enabling targeted and long-term therapeutic delivery directly to brain tissue.

Therapeutic: Neuromodulation-Neurostimulation; Drug Delivery

Anthony DePasqua Co-Founder & CEO

EnClear Therapies, Inc. (Cambridge, MA, USA) incorporated in Delaware, 2018 as a spin out of QurAlis, Inc. a biotechnology company working in the ALS space. EnClear was founded to overcome challenges in safely accessing the central nervous system to improve therapeutic options for neurodegenerative and neuro oncologic diseases. EnClear is developing the EnTrega CSF management platform. The EnTrega Platform’s primary goal is to increase the bioavailability of therapies within the central nervous system to improve therapeutic effect. In pre-clinical models, The EnTrega platform has been shown to increase tissue distribution of therapies, by as much as 1,000X when compared to standard of care. Combining safe, repeatable access to CSF with next generation sensing and CSF control, the EnTrega Platform improves therapeutic effect and decreases off target toxicity by increasing the distribution of therapies to where they are most effective. While providing real-time patient feedback and repeatable, automated CSF sampling for diagnostics.

Therapeutic: Drug Delivery; Neurology

Jay Cormier President & CEO

Eyedaptic (Laguna Hills, CA, USA) is pioneering the use of Augmented Reality (AR), powered by Artificial Intelligence (AI), to address the large unmet eye care need of Retinal Diseases, such as Macular Degeneration, afflicting over 200 million people worldwide. Effectiveness has been demonstrated, leading to strong user adoption and traction. These ultralight smart glasses adapt not only to the user’s vision but also their habits and environment, thereby empowering users to maintain their independence and quality of life across the widest range of tasks.

Therapeutic: Ophthalmology; Augmented Reality, Artificial Intelligence, Digital Health

Myles Greenberg Co-Founder & Exec Chair

Focused Therapeutics (FT) (Salt Lake City, UT) is a start-up medical device company developing Focused Electric Field (FEF) technology for use in cardiac ablation procedures for the treatment of arrhythmias. Arrythmias are often treated by ablating or electrically isolating abnormal substrates, enabling the heart to resume its normal rhythm. FEF technology is designed to address a significant unmet need in the rapidly growing $4 billion cardiac ablation market - the inability of current products to treat thick cardiac tissue in both the atria and ventricles and to allow for the treatment of potentially fatal arrythmias like ventricular tachycardia. FEF does so by “focusing” standard RF or pulsed field generated electric fields more deeply into the myocardium than occurs with commercially available ablation catheters. To date, Focused Therapeutics has demonstrated that the FEF technology works in a benchtop laboratory model and has also confirmed these initial results by demonstrating the safety and effectiveness of the technology in multiple in vivo animal experiments. The next stage is to fully develop a human clinical product and demonstrate success in treating human patients. To achieve these goals, FT is currently raising a Series A round of financing.

Therapeutic: Cardiovascular; Electrophysiology

Leo Smit CEO

Revolutionizing cartilage recovery: Hy2Care’s (Geleen, Limburg, the Netherlands) CartRevive® hydrogel implant realizes optimal regeneration of cartilage defects. After sports mishaps, slips, or falls, our patented hydrogel offers a scaffold of joint-matching composition, guiding natural cell growth and enabling the body to heal itself. Currently under clinical examination in the Netherlands for EU approval, with US trials coming up. Dive into the future of joint repair with us!

Therapeutic: Orthopedics; Regenerative Medicine

Allen Waziri CEO & Co-founder

iCE Neurosystems (Washington, DC) is a commercial-stage neurotechnology startup providing a comprehensive EEG-based device-and-data platform to transform brain care in the critically ill. Our FDA-cleared single-use/disposable devices and integrated software platform are deployed and revenue-generating at 5 major healthcare systems (nearly 300 patients monitored to date). We were recently selected as a Finalist for the Medtech Innovator Execution Award and a member of the inaugural AHA/MTI Heart and Brain Accelerator. Our proven major market verticals include stroke and cardiac arrest.

Therapeutic: ICU-Critical Care

Peter Fischer President & CEO

InkSpace Imaging (Pleasanton, CA, US) pioneers a transformative printed electronics platform for advanced medical devices, initially prioritizing best-in-class MRI receive coils. Our lightweight, flexible coils deliver unparalleled imaging quality, while also speeding up scan times, enhancing patient comfort, reducing the necessity for anesthesia, and minimizing additional procedures—all of which drive down costs. Our technology democratizes access to top-tier diagnostics and promises a rapid ROI. Fully compatible with MRI systems and reimbursement models, our FDA-cleared coils tap into a $2B MRI coil market.

Therapeutic: Imaging; MR-guided High-Intensity Focused Ultrasound and Cryoablation

Albert Hill CEO

Katomed (San Diego, CA, USA) is developing an automation platform for precision-sensitive tasks in spine surgery.

Therapeutic: Minimally Invasive Surgery

Jake Edick CEO

Magsorbeo Biomedical (Detroit, MI, USA) is a preclinical stage medical device development and manufacturing company founded by a team of industry veterans specializing in bioabsorbable metal implants. These fully absorbable implants are built from the patent pending and Magsorbeo owned Curasorb alloy to revolutionize treatment, improve outcomes, and reduce healthcare costs by eliminating removal procedures and life-threatening complications such as infections by absorbing and restoring tissue to its natural physiology, while maintaining performance of titanium implants.

Therapeutic: Biomaterials; Surgery

Jeroen Nieuwenhuis CEO

Nostics (Amsterdam, the Netherlands & Cambridge, MA, USA) is developing the rapid Point of Care diagnostics solution for infectious diseases to support healthcare professionals with confirmation of infection and identification of the bacterial species in <15 minutes, to prevent the over- and misuse of antibiotics and resulting complications. Starting with our first application targeting the 400M people/year who suffer from a Urinary Tract Infection. Powered by AI and Nanophotonics.

Therapeutic: Diagnostics; Infectious Diseases

Stuart Mitchell Founder & CEO

Novuson (Bothell, WA, USA) is clearing the way for safer surgeries by eliminating excessive tissue damage and the associated smoke that obscures the surgeons field of view. Novuson developed the world's first Direct Therapeutic Ultrasound (DTU) surgical instruments for minimally invasive, robotic, and other surgical specialties. DTU is an alternative surgical energy modality that doesn't burn or char tissue and is more efficient than current technologies, making surgeries more precise, without risking the health and safety of the patients or the healthcare workers. Eliminating surgical smoke reduces health risks and potentially minimizes related complications. Novuson is positioned to commercialize their first devices pending FDA clearance and has $500k pre-commercialization revenue through a surgical robotics collaboration. They have 16 issued and pending US and International patents. Novuson’s vision is to improve surgical safety and patient outcomes, ultimately reducing healthcare costs.

Therapeutic: Minimally Invasive Surgery; Robotic Surgery

Rodney Schutt President & CEO

Orion Innovations Inc. is a US-based healthcare company led by a proven management team with a track record of scaling businesses & exits; focused on minimizing high-cost clinical errors via single-use, IP protected solutions to global needs. Orion has $600K in historical revenue and multiple investor return and exit opportunities over the short/mid/long term with an Incubate, Commercialize, and Exit (ICE) pipeline.

Therapeutic: Infusion; Dental

Manios Dimitrakakis CEO

Panda Surgical (London, UK) is developing a next-generation handheld robotics platform which offers neurosurgeons enhanced dexterity and control in confined spaces, enabling more surgeons to perform complex minimally invasive procedures. This robotic system consists of a series of interchangeable 3mm-diameter wristed instruments controlled by an ergonomically-designed handheld controller. The Panda Surgical system allows neurosurgeons to penetrate deep confined spaces and perform previously impossible delicate maneuvers. This can lead to more effective procedures with more tumor removed, safely and precisely.

Therapeutic: Robotics; Neurosurgery

Chris Darland CEO

Peerbridge Health (Nashville, TN, USA) is pioneering the next generation of AI-enabled wearable technology to solve the affordability and accessibility issues facing the US Health System. By combining best-in-class ECG signal fidelity with physics-based, explainable AI, the Cor device can deliver hospital grade diagnostics (Heart Failure, Obstructive Sleep Apnea) and monitoring (Ejection Fraction, Cardiac Output, 12 lead ECG) with much more to come.

Therapeutic: Cardiovascular; Diagnostics

Mark Nelson President & CEO

Precision Epigenomics (Tucson, AZ) is a molecular diagnostics company in the cancer detection space. Precision Epigenomics features liquid biopsy technology for early cancer detection.  We have created EPISEEK multi cancer detection test which can detect over 20 different cancers from a single blood draw. 

Therapeutic: Diagnostic

James Lancaster CEO

Solenic Medical, Inc. (Addison, Texas, USA) is clinical stage company pioneering a non-invasive solution for infected implants, like prosthetic knees and hips, utilizing alternating magnetic fields (AMF). This technology, designated a U.S. FDA Breakthrough Device, targets infections complicated by biofilms on implant surfaces. In-vitro and large animal studies demonstrated a significant bacteria reduction within safe temperature ranges. The solution targets safe and effective treatment for implant infections.

Therapeutic: Orthopedics-Spine; Infection Treatment

Jeff Cambra CEO

SpinaFX (Toronto, ON, Canada) is a medical treatment solution company providing rapid and sustained relief to patients with back pain due to contained lumbar herniated discs, using innovative, minimally invasive image-guided therapy.

Therapeutic: Pain management; Minimally Invasive Image-Guided Therapy

Justin Zenanko CEO & Co-founder

The patented SynerFuse™ (Eden Prairie, Minnesota, USA) procedure, Electric Transforaminal Lumbar Interbody Fusion (e-TLIF™), combines fusion with direct nerve stimulation to address chronic low back and leg pain that is unaddressed in traditional spinal fusion surgery. The aims of SynerFuse is to decrease number of back fusions/surgeries related to pain and address chronic pain at the point of surgery.

Therapeutic: Neuromodulation-Neurostimulation; Spinal Fusion

Westbrook Weaver Founder & CEO

Tempo Therapeutics (San Diego, CA, USA) is a clinical-stage therapeutic biomaterials company focused on tissue engineering for reconstructive surgical oncology. With patented injectable MAP biomaterials, Tempo catalyzes inflammation-free healing in immunodeficient patients, accessing new biological pathways to rebuild tissue inside patients, restoring function to damaged or diseased organs and transforming patient outcomes.

Therapeutic: BIomaterials; Surgical Oncology

Martin Cook CEO

Company description

VenstraMedical (Newcastle, Australia and Minneapolis, MN, USA) has developed the smallest and most powerful next-generation temporary cardiac assist device, a percutaneous catheter-based pump (pVAD) protected by 7 issued patents, that allows for the device to be collapsed into a low-profile 9Fr catheter for insertion. Once expanded across the aortic valve the device provides full cardiac support, to over 7L/min, for cardiogenic shock patients and patients undergoing high risk coronary interventions.  We are looking to raise our Series B round to fund clinical trials with strong strategic and institutional interest.

Technology description

Our novel pVAD technology is the most powerful and smallest pVAD technology that we know, able to provide over 7L/min at physiological pressures and provide total left ventricular support for cardiogenic shock and other critically ill patients. Total support has been shown to reduce infarct size for heart attack patients and the recent DanGer shock trial has validated the use of pVAD technology in cardiogenic shock patients. The technology is based on 7 granted patents and no catheter or sheath larger than 9Fr is used in the percutaneous, cath lab, implant procedure. 

Therapeutic: Cardiovascular

Jeremy Stueven CEO

Vitazi.ai (Santa Fe, NM, USA) provides a complete solution for diabetic retinopathy screening, eliminating the need for dilation and specialized training. Our VitaziView™ camera and VitaziCapture™ desktop application connect to OcuIoInsights™—our platform integrating retinal image capture, teleretinal services, AI insights, and a medical image database. While awaiting FDA 510K clearance for AI use, Vitazi.ai offers a teleretinal service with ophthalmologists reading scans via the Vitazi Image Grading Portal. The platform integrates with most EHR systems, delivering a comprehensive solution for clinicians and diagnostic centers.

Therapeutic: Artificial Intelligence; Telemedicine

Hannah Zhang CEO

Zepto Life Technology (St. Paul, Minnesota, United States) is focused on improving diagnostics and patient care worldwide, particularly in sepsis and invasive fungal infections. They are developing a highly multiplexed panel of pathogens using Nobel prize-winning Giant Magnetoresistance (GMR) technology to bypass traditional culture methods. In addition to creating this innovative tool, Zepto operates diagnostic labs and offers Contract Research Organization (CRO) services to help other companies bring their diagnostic tests to market.

Therapeutic: Diagnostics